Boehringer Ingelheim
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Description
Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health.
Investor Profile
Boehringer Ingelheim has backed more than 9 startups, with 0 new investments in the last 12 months alone. The firm has led 4 rounds, about 44% of its total and boasts 2 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C, Undisclosed, Series B rounds (top funding stages).
- Majority of deals are located in United States, Kenya, Austria.
- Strong thematic focus on Health Care, Biotechnology, Medical.
Stage Focus
- Series C (22%)
- Undisclosed (11%)
- Series B (11%)
- Debt Financing (11%)
- Corporate Round (11%)
- Grant (11%)
- Post Ipo Equity (11%)
- Series A (11%)
Country Focus
- United States (44%)
- Kenya (11%)
'/%3e%3c/defs%3e%3cpath fill='%23fff' d='M-120-80h240V80h-240z'/%3e%3cpath d='M-120-80h240v48h-240z'/%3e%3cpath fill='%23060' d='M-120 32h240v48h-240z'/%3e%3cg id='b'%3e%3cuse xlink:href='%23a' stroke='%23000'/%3e%3cuse xlink:href='%23a' fill='%23fff'/%3e%3c/g%3e%3cuse xlink:href='%23b' transform='scale(-1 1)'/%3e%3cpath fill='%23b00' d='M-120-24v48h101c3 8 13 24 19 24s16-16 19-24h101v-48H19C16-32 6-48 0-48s-16 16-19 24z'/%3e%3cpath id='c' d='M19 24c3-8 5-16 5-24s-2-16-5-24c-3 8-5 16-5 24s2 16 5 24'/%3e%3cuse xlink:href='%23c' transform='scale(-1 1)'/%3e%3cg fill='%23fff'%3e%3cellipse rx='4' ry='6'/%3e%3cpath id='d' d='M1 5.85s4 8 4 21-4 21-4 21z'/%3e%3cuse xlink:href='%23d' transform='scale(-1)'/%3e%3cuse xlink:href='%23d' transform='scale(-1 1)'/%3e%3cuse xlink:href='%23d' transform='scale(1 -1)'/%3e%3c/g%3e%3c/svg%3e)
- Austria (11%)
- Switzerland (11%)
- Canada (11%)
- Belgium (11%)
Industry Focus
- Health Care
- Biotechnology
- Medical
- Therapeutics
- Pharmaceutical
- Medical Device
- Telehealth
- Veterinary
- Electronic Health Record (Ehr)
- Health Diagnostics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
